- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02092896
Liraglutide as add-on to Insulin in Type 1 Diabetes (T1DMLIRA)
Treatment With Liraglutide as add-on to Insulin in Type 1 Diabetic Patients. Effects on Glycemic Control and Counterregulation and Cognitive Performance During Hypoglycaemia
The purpose of this study is to:
Part 1:
To investigate how 12 weeks treatment with liraglutide affects glycemic control in poorly controlled patients and how the treatment affects gastric emptying rate during hypoglycemia.
Part 2:
To investigate how 12 weeks treatment of type 1 diabetic patients with liraglutide affects counterregulatory hormones and cognitive performance during hypoglycemia.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 3
Contactos e Locais
Locais de estudo
-
-
Copenhagen
-
Hvidovre, Copenhagen, Dinamarca, 2650
- Dept. of Endocrinology, Hvidovre University Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Age: 18-70 years
- BMI: 18-28
- HbA1c ≥ 8 %
- No residual β-cell function (glucagon test with c-peptide < 60 pM)
- Caucasian
- Diagnosed with type 1 diabetes at 5 to 40 years of age (both inclusive).
- Remission phase must be completed
- Female participants must use adequate contraception
- Informed consent
Exclusion Criteria:
- Overt diabetes complications; creatinin > 130 µM, proliferative retinopathy, macroalbuminuria.
- Autonomic neuropathy (RR-variation </=10 beats/min) and/or Orthostatic hypotension (OH).
- Anemia, Hb concentration; female <7.0 mmol/l, male<8.0 mmol/l
- Pregnancy or lactation
- Epilepsy
- Use of antiepileptic medication
- Use of beta blockers
- Previously apoplexy cerebri.
- Any use of benzodiazepine within the last month
- Any use of neuroleptic drugs within the last six months
- Self-perceived hearing loss
- Alcohol or drug abuse
- Allergy to the medication or placebo.
- Treatment with any medication affecting glucose metabolism.
- Any disorder which in the investigators opinion could interfere with the safety and results of the trial
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador de Placebo: Placebo + Insulin + Study 2
Study 2: Cognitive performance test
|
Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks.
At baseline and week 12 study 1 is performed.
Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks.
At baseline and week 12 study 2 is performed.
|
|
Experimental: Liraglutide + Insulin + Study 2
Study 2: Cognitive performance test
|
Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks.
At baseline and week 12 study 1 is performed.
Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks.
At baseline and week 12 study 2 is performed.
|
|
Experimental: Liraglutide + Insulin + Study 1
Study 1: Gastric emptying test
|
Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks.
At baseline and week 12 study 1 is performed.
Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks.
At baseline and week 12 study 2 is performed.
|
|
Comparador de Placebo: Placebo + Insulin + Study 1
Study 1: Gastric emptying test
|
Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks.
At baseline and week 12 study 1 is performed.
Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks.
At baseline and week 12 study 2 is performed.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
Change from baseline in HbA1c (glycosylated haemoglobin)
Prazo: Week 0, week 12
|
Week 0, week 12
|
|
Changes from baseline in EEG and cognitive performances
Prazo: week 0, week 12
|
week 0, week 12
|
|
Change from baseline in gastric emptying rate
Prazo: week 0, week 12
|
week 0, week 12
|
Medidas de resultados secundários
Medida de resultado |
Prazo |
|---|---|
|
Change from baseline in glycemic control (CGM)
Prazo: week 0, week 12
|
week 0, week 12
|
|
Change from baseline in total daily insulin dose
Prazo: week 0, week 12
|
week 0, week 12
|
|
Changes from baseline in the counterregulatory hormone responses during hypoglycemia
Prazo: week 0, week 12
|
week 0, week 12
|
|
Change from baseline in body weight
Prazo: week 0, week 12
|
week 0, week 12
|
|
Change from baseline in auditory evoked potentials (AEP) during hypoglycemia
Prazo: week 0, week 12
|
week 0, week 12
|
|
Change from baseline in corrected QTc-interval (QTc) during hypoglycemia
Prazo: week 0, week 12
|
week 0, week 12
|
|
Change from baseline in hypoglycemic symptom score
Prazo: week 0, week 12
|
week 0, week 12
|
Outras medidas de resultado
Medida de resultado |
Prazo |
|---|---|
|
Frequency of Hypoglycemic episodes
Prazo: Week 0, week 12
|
Week 0, week 12
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Christian SS Frandsen, MD, Hvidovre University Hospital
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Distúrbios do Metabolismo da Glicose
- Doenças Metabólicas
- Doenças do sistema imunológico
- Doenças autoimunes
- Doenças do Sistema Endócrino
- Diabetes Mellitus
- Diabetes Mellitus, Tipo 1
- Hipoglicemiantes
- Efeitos Fisiológicos das Drogas
- Hormônios
- Hormônios, Substitutos Hormonais e Antagonistas Hormonais
- Incretinas
- Liraglutida
Outros números de identificação do estudo
- 2012-002526-67 (Número EudraCT)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .